2. Anti-infection Cell Cycle/DNA Damage Membrane Transporter/Ion Channel
  3. Bacterial DNA/RNA Synthesis Potassium Channel
  4. Sideromycin 7

Sideromycin 7 is an antibacterial agent. Sideromycin 7 forms a 7-Bi3+ coordination complex with bismuth citrate, exerting a three-pronged antibacterial mode of action: direct DNA binding to induce damage and arrest replication, suppression of KdpC synthesis to block KdpFABC-mediated potas-sium transport, and inhibition of ATP production. Sideromycin 7 exhibits potent antibacterial activity against Ciprofloxacin (HY-B0356)-resistant Pseudomonas aeruginosa strains. Sideromycin 7 exerts antibiofilm activity against Pseudomonas aeruginosa. Sideromycin 7 can be used for the research of ciprofloxacin-resistant Pseudomonas aeruginosa infection.

For research use only. We do not sell to patients.

Sideromycin 7

Sideromycin 7 Chemical Structure

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Sideromycin 7 Related Antibodies

Top Publications Citing Use of Products

View All DNA/RNA Synthesis Isoform Specific Products:

View All Isoforms
RNASE L DNA Polymerases RNA Polymerases Helicases DNA Ligase

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Sideromycin 7 is an antibacterial agent. Sideromycin 7 forms a 7-Bi3+ coordination complex with bismuth citrate, exerting a three-pronged antibacterial mode of action: direct DNA binding to induce damage and arrest replication, suppression of KdpC synthesis to block KdpFABC-mediated potas-sium transport, and inhibition of ATP production. Sideromycin 7 exhibits potent antibacterial activity against Ciprofloxacin (HY-B0356)-resistant Pseudomonas aeruginosa strains. Sideromycin 7 exerts antibiofilm activity against Pseudomonas aeruginosa. Sideromycin 7 can be used for the research of ciprofloxacin-resistant Pseudomonas aeruginosa infection[1].

In Vitro

Sideromycin 7 acts synergistically with bismuth citrate to exhibit potent antibacterial activity against Ciprofloxacin (HY-B0356)-resistant Pseudomonas aeruginosa strains, with MICs 3.2- to 21-fold lower than conventional quinolone antibiotics[1].
Sideromycin 7 (combined with bismuth citrate; 18 days daily passaging) does not induce resistance development in Pseudomonas aeruginosa 859 or 7034 after 18 days of serial passaging in vitro[1].
Sideromycin 7 (combined with bismuth citrate; 4× MIC; 24 h) significantly inhibits Pseudomonas aeruginosa 541 biofilm formation by 78% after 24 h of incubation in vitro[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Sideromycin 7 Related Antibodies
In Vivo

Sideromycin 7 (8 mg/kg; in situ injection; once daily; 3 days) reduces P. aeruginosa biofilm bacterial burden and improves wound healing in a subcutaneous mouse infection model[1].
Sideromycin 7 (2-32 mg/kg; intraperitoneal injection; two doses total) reduces bacterial burden and lung inflammation in a neutropenic mouse lung infection model[1].
Sideromycin 7 (32 mg/kg; intraperitoneal injection; once daily; 28 days) is well-tolerated in mice with no observable toxicity or gut microbiota disruption[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/c (female, 4-6 weeks old, 18-20 g, subcutaneous implantation of PDMS sheets precoated with P. aeruginosa 7034 biofilms)[1]
Dosage: 8 mg/kg
Administration: in situ injection; once daily; 3 days
Result: Reduced log10 CFU/mL of bacterial burden on PDMS sheets compared to vehicle control.
Improved wound healing with reduced visible inflammation compared to vehicle control.
Decreased necrotic areas and inflammatory infiltrates in skin and muscle tissue relative to vehicle control.
Animal Model: SPF ICR (female, 6 weeks old, 20-22 g, cyclophosphamide-induced neutropenic, intranasal inoculation with P. aeruginosa 535 and 541)[1]
Dosage: 2, 5, 8 32 mg/kg
Administration: intraperitoneal injection; two doses total (2 hours and 12 hours post-infection)
Result: Reduced log10 CFU/g of lung tissue compared to vehicle control for P.
aeruginosa 541 at 5 mg/kg, 8 mg/kg, or 32 mg/kg.
Reduced log10 CFU/g of lung tissue compared to vehicle control for P.
aeruginosa 535 at 8 mg/kg.
Reduced inflammatory cell infiltration in lung tissue relative to vehicle control.
Molecular Weight

573.61

Formula

C28H36FN5O7
SMILES

CC(N(CCCCCNC(CCC(N1CCN(CC1)C2=C(C=C3C(C(C(O)=O)=CN(C3=C2)C4CC4)=O)F)=O)=O)O)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Sideromycin 7 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Sideromycin 7Sideromycin7Sideromycin-7BacterialDNA/RNA SynthesisPotassium ChannelKcsAmurine modelsoxidative phosphorylation complexes IVoxidative phosphorylation complexes VPseudomonas aeruginosaKdpFABCgut microbiotapotassium transportKdpCciprofloxacin-resistant Pseudomonas aeruginosaDNA integrityInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Sideromycin 7
Cat. No.:
HY-181966
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.